Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Nivolumab in Combination With Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

NCT04119336 is registered in ClinicalTrials.gov with Andrew Yee, MD as lead sponsor.

NCT NCT04119336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04119336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Nivolumab in Combination With Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Lead sponsor
Andrew Yee, MD
Phase
Phase 2
Overall status
Terminated
Start date
February 14, 2020
Completion date
March 30, 2022
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, relapsed multiple myeloma